美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

33.56

+0.24590.74%

盤後：33.560.00000.00%16:10 EDT

成交量：528

成交額：1.77萬

市值：1,342.44萬

市盈率：- -

高：33.56

開：33.41

低：33.41

收：33.32

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.45

換手率：0.13%

股息：0.08

股息率：0.24%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

石藥集團SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心啓動

丹納赫（DHR）旗下兩子公司聯合推出Cas9 mRNA解決方案賦能基因編輯研發加速落地

吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir

上海萊士(002252.SZ)：「SR604注射液」進入Ⅲ期臨床試驗

上海萊士：SR604注射液進入Ⅲ期臨床試驗

強生：鋭珂捷®埃萬妥單抗注射液在中國上市

石藥集團(01093)：SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心正式啓動

智通财经网

苑東生物：EP-0226片完成I期臨床試驗推進II期籌備

陽光諾和(688621.SH)：在研項目BTP0427的臨床試驗申請獲得批准

陽光諾和：BTP0427規格I、II獲臨床試驗批准

ST百靈(002424.SZ)子公司糖寧通絡乳膏獲批臨床試驗

ST百靈：全資子公司獲2026年藥物臨床試驗批准通知書

港股異動 | 恒瑞醫藥(01276)尾盤漲近4% 同日獲兩份臨床試驗批准覆蓋銀屑病和卒中預防

香港施政報告：邀請廣深企業參與大學城建設河套大灣區國際臨床試驗所投入運作

恒瑞醫藥(01276.HK)：注射用瑞卡西單抗獲得藥物臨床試驗批准通知書

健康快訊：一種用於磁共振成像檢查的新造影劑可更早發現肺癌

Contineum 股價下跌 9.9%，原因是其與強生合作研發的抗抑鬱藥中期臨床試驗失敗。

吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章

吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及

吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BMED/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.5609,"timestamp":1789588800000,"preClose":33.315,"halted":0,"volume":528,"hourTrading":{"tag":"盘后","latestPrice":33.5609,"preClose":33.5609,"latestTime":"16:10 EDT","volume":6,"amount":201.36539999999997,"timestamp":1789589403908,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007381059582770491,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"盤後交易","change":0.2459,"latestTime":"09-16 16:56:13 EDT","open":33.41,"high":33.5609,"low":33.41,"amount":17687,"amplitude":0.004529,"askPrice":50.2,"askSize":200,"bidPrice":16.74,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":33.315,"sharesOutstanding":360000,"nav":33.210436,"aum":13284174.4,"dividendRate":0.002375,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.5609,"preClose":33.5609,"latestTime":"16:10 EDT","volume":6,"amount":201.36539999999997,"timestamp":1789589403908,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.449898,"impliedVol":0.0628,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.449898,"shares":400000,"dividePrice":0.0797,"high":33.5609,"amplitude":0.004529,"preClose":33.315,"low":33.41,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.5609,"eps":0,"divideRate":0.002375,"volume":528,"delay":0,"ttmEps":0,"open":33.41,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":33.0422,"twentyDayClose":32.666,"sixtyDayClose":28.5621},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667989312","title":"石藥集團SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2667989312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667989312?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 21:55","pubTimestamp":1789566903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667985488","title":"丹納赫（DHR）旗下兩子公司聯合推出Cas9 mRNA解決方案 賦能基因編輯研發加速落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2667985488","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667985488?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 20:57","pubTimestamp":1789563457,"startTime":"0","endTime":"0","summary":"金吾财讯 | 丹纳赫 旗下两家子公司——集成DNA技术公司与Aldevron宣布推出联合研发的科研级S.p. Cas9 mRNA解决方案，涵盖野生型及SpyFi高保真两种形式，旨在加速CRISPR基因编辑项目从早期研究向符合CGMP标准的临床开发转型。该联合方案结合了IDT在CRISPR基因工程与设计方面的专业知识，以及Aldevron在mRNA领域的规模化生产能力。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306117","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1366333091.USD","LU1923622614.USD","BK4534","LU0708995401.HKD","XT","LU0114720955.EUR","SYNB","TARK","CRSP","IE000M9KFDE8.USD","LU0432979614.USD","LU0689472784.USD","SG9999001176.USD","LU0390134368.USD","LU2106854487.HKD","BMED","BK4585","IE00BQXX3F31.USD","LU0289739343.SGD","LU1551013342.USD","SG9999004303.SGD","LU1267930730.SGD","WDNA","LU0289961442.SGD","LU1974910355.USD","IDNA","GNOM","LU2063271972.USD","DHR","FMED","LU2355687059.USD","DTEC","ARKG","NBDS","KOMP","LU0528227936.USD","FWD","LU2125910336.SGD","LU1804176565.USD","LU1551013425.SGD","LU1791710582.SGD","SGXZ57979304.SGD","LU0820561818.USD","LU2211814178.USD","LU0943347566.SGD","LU0289960550.SGD","HELX","LU0882574055.USD","IE00BQXX3C00.GBP","IE0004445239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164691459","title":"吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164691459?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","IBB","SG9999015952.SGD","LU1023059063.AUD","IE00B7SZLL34.SGD","LU0122379950.USD","LU1934455277.USD","LU2087621335.USD","BK4583","LU1037948541.HKD","LU0861579265.USD","LU0058720904.USD","LU0882574055.USD","IE00BKVL7J92.USD","SG9999015978.USD","IE00BSNM7G36.USD","LU1066051498.USD","LU1571399168.USD","TBXU","TMED","LU2089984988.USD","SG9999015986.USD","LU1430594728.SGD","LU1674673428.USD","GILD","BK4585","LU1585245621.USD","LU0965509101.SGD","LU0965509283.SGD","IE0002270589.USD","LU2468319806.SGD","LU0320765992.SGD","LU1066053197.SGD","LU2324357040.USD","LU0234570918.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0965508806.USD","LU0859254822.USD","LU0965509010.AUD","BK4139","LU0289739699.SGD","LU2357627491.SGD","LU1037948897.HKD","BK4566","BMED","BK4588","BK4532","IE00BZ1G4Q59.USD","IBBQ","BK4578","BK4568","LU0114720955.EUR","LU1778281490.HKD","MEDI","IE00B19Z3B42.SGD","BK4550","LU0889565916.HKD","BBH","LU1057294990.SGD","LU1934455863.HKD","LU1934455194.USD","LU2112291526.USD","BIB","LU0109394709.USD","LU1674673691.USD","LU0823416689.USD","LU1839511570.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988673","title":"上海萊士(002252.SZ)：「SR604注射液」進入Ⅲ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667988673?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:56","pubTimestamp":1789559791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士 发布公告，公司在研产品“SR604注射液”于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了“血友病A/B患者出血发作的预防治疗”Ⅲ期临床试验登记信息，试验名称：评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性和安全性的单臂、多中心Ⅲ期临床试验试验目的：评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBQ","BK0028","IBBJ","BK0196","BK0188","MDTX","BK0239","BK0046","002252","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667498863","title":"上海萊士：SR604注射液進入Ⅲ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667498863","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667498863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:51","pubTimestamp":1789559491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","PSYK","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667885079","title":"強生：鋭珂捷®埃萬妥單抗注射液在中國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667885079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667885079?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:49","pubTimestamp":1789559357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","IPOS","LU1162221912.USD","SGXZ57979304.SGD","LU0943347566.SGD","LU0122379950.USD","LU0689472784.USD","IE00B2B36J28.USD","FHLC","BK4585","LU0738911758.USD","JDOC","IE0034235303.USD","IE00B1BXHZ80.USD","LU2403377893.USD","LU0345769128.USD","IYH","LU0098860793.USD","LU1280957306.USD","LU1196500208.SGD","BMED","FTXH","XLV","LU1894683348.USD","VHT","LU1061106388.HKD","LU0345770308.USD","LU1043141123.HKD","BK4532","IHE","IE000SO60NU8.SGD","LU2756315318.SGD","LU2417539215.USD","LU0162691827.USD","LU1074936037.SGD","GDOC","TRUH","IXJ","MEDX","LU0426412945.USD","LU1718418525.SGD","LU0795875086.SGD","JNJ","LU0426417589.USD","IE00B4R5TH58.HKD","LU0203345920.USD","PJP","BK4581","SG9999001440.SGD","RXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667020436","title":"石藥集團(01093)：SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2667020436","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667020436?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 18:39","pubTimestamp":1789555160,"startTime":"0","endTime":"0","summary":"石药集团(01093)发布公告，集团开发的SYH2069注射液(“该产品”)用于治疗成人2型糖尿病的II期临床试验(SYH2069-003)已在中国首个研究中心正式启动。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg6.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg6.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","SG9999004220.SGD","IE0008369823.USD","LU1226288253.USD","01093","LU0072913022.USD","KURE","LU1226288170.HKD","LU1813983027.USD","BMED","LU1226287529.USD","LU2039709279.SGD","IE00B543WZ88.USD","BK1521","LU0067412154.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1328277881.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","IBBJ","LU1226287792.SGD","BK1191","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","LU0501845795.SGD","LU0140636845.USD","LU1008478684.HKD","LU0326950275.SGD","HK0000165453.HKD","LU1951186391.HKD","IBBQ","LU0315179316.USD","MDTX","PSYK","IE0008368742.USD","LU1807302812.USD","LU1152091754.HKD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601469","title":"苑東生物：EP-0226片完成I期臨床試驗 推進II期籌備","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601469","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601469?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:36","pubTimestamp":1789551391,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601451","title":"陽光諾和(688621.SH)：在研項目BTP0427的臨床試驗申請獲得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601451","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601451?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:34","pubTimestamp":1789551264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及全资子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP0427的临床试验申请获得批准。BTP0427拟用于治疗射血分数降低的慢性心力衰竭，适用于心脏收缩功能障碍的慢性心力衰竭患者的对症治疗，作为替代疗法，用于已经接受相同剂量的β受体阻滞剂和窦房结If电流抑制剂联合治疗且病情得到控制的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","PSYK","688621","BMED","MDTX","BK0216","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667019476","title":"陽光諾和：BTP0427規格I、II獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667019476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667019476?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:30","pubTimestamp":1789551020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","MDTX","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667609196","title":"ST百靈(002424.SZ)子公司糖寧通絡乳膏獲批臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667609196","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667609196?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:02","pubTimestamp":1789549346,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST百灵(002424.SZ)发布公告，近日，公司全资子公司百灵毓秀(珠海)医药有限公司(简称“百灵毓秀”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司糖宁通络乳膏临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于糖尿病足溃疡的临床试验。本次公司全资子公司百灵毓秀收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意糖宁通络乳膏开展用于糖尿病足溃疡的临床试验，系公司糖宁通络管线重要阶段性研发成果，有利于推进公司糖尿病并发症“内服+外用”治疗体系布局，糖宁通络乳膏获得临床试验批准暂不会对公司当期业绩产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0077","002424","IBBJ","BMED","BK0188","MDTX","BK0183","PSYK","IBBQ","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667099276","title":"ST百靈：全資子公司獲2026年藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667099276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667099276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 16:59","pubTimestamp":1789549183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BMED","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605559","title":"港股異動 | 恒瑞醫藥(01276)尾盤漲近4% 同日獲兩份臨床試驗批准 覆蓋銀屑病和卒中預防","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605559","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667605559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 15:49","pubTimestamp":1789544947,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药尾盘涨近4%。截至发稿，涨3.88%，报45.5港元，成交额1.53亿港元。消息面上，9月15日，恒瑞医药公告称，子公司福建盛迪医药的HRS-4139片获国家药监局临床试验批准，同意开展中重度斑块状银屑病的临床试验。同日，子公司广东恒瑞医药的注射用瑞卡西单抗获临床试验批准，同意开展Ⅲ期临床试验，适应证为用于颅内动脉粥样硬化性狭窄的成人患者以降低卒中复发风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1655091616.SGD","LU2097828631.EUR","BK0188","KCAI","BK0012","BK1191","BMED","LU0359201885.HKD","BK0196","BK0028","MDTX","LU2097828474.EUR","LU2097828557.USD","LU2148510915.USD","LU2097828714.EUR","LU2543165471.USD","LU2289578879.USD","LU1997245177.USD","IBBJ","LU1064131003.USD","LU1255011170.USD","LU1781817850.SGD","LU1997245094.SGD","LU1820825898.SGD","LU2097828805.USD","600276","LU2580892862.HKD","LU1328615791.USD","LU2328871848.SGD","BK4588","BK4585","LU2488822045.USD","LU1997244956.HKD","VXUS","LU2580892789.USD","BK0060","LU0359201612.USD","LU1146622755.USD","BK0183","LU2495084118.USD","BK0239","LU1969619763.USD","PSYK","IBBQ","LU0405327148.USD","LU0405327494.USD","01276","LU0359202008.SGD","LU1580142542.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667672921","title":"香港施政報告：邀請廣深企業參與大學城建設 河套大灣區國際臨床試驗所投入運作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667672921","media":"港股一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667672921?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 13:07","pubTimestamp":1789535220,"startTime":"0","endTime":"0","summary":"李家超指，将邀请广深创新及科技园有限公司及新田科技城有限公司加入开发行列，参与大学城建设，以加快项目建造发展。李家超同时表示，河套香港园区的粤港澳大湾区国际临床试验所已投入运作，由香港特区政府全资拥有并委托香港大学营运，与深圳园区协同推动医疗创新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkyx/2026-09-16/doc-iniryzmc4906916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","IBBJ","BMED","PSYK","159983","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667204626","title":"恒瑞醫藥(01276.HK)：注射用瑞卡西單抗獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667204626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667204626?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 07:38","pubTimestamp":1789515492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","BMED","IBBQ","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667621189","title":"健康快訊：一種用於磁共振成像檢查的新造影劑可更早發現肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2667621189","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667621189?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 02:52","pubTimestamp":1789498325,"startTime":"0","endTime":"0","summary":"健康快讯：一种用于磁共振成像检查的新造影剂可更早发现肺癌《Health Rounds》荣获2026年出版商通讯奖“最佳科学通讯”奖项，每周二和周四发布。今天我们重点介绍一种可能改变游戏规则的磁共振成像实验性造影剂，它有望在肺癌肿瘤尚小、治疗选择更多时就发现病灶。新型造影剂可在MRI检查中发现微小肺部肿瘤研究人员发现，一种用于磁共振成像检查的新型造影剂，可能使医生在比目前更早的阶段诊断出肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4S4571FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210536198.USD","IHE","LU2487616109.SGD","PJP","LU0058720904.USD","IE0002141913.USD","IE00BLSP4239.USD","LU0466842654.USD","BK4585","FHLC","LU0964807845.USD","IE000M9KFDE8.USD","LU2471134796.USD","RXL","JDOC","LU1043141396.HKD","TRUH","MEDX","LU0820561818.USD","BMED","LU1674673428.USD","LU0072461881.USD","LU0345770308.USD","BK4592","LU1244550221.USD","IE00B1BXHZ80.USD","LU0912757837.SGD","BK4581","IYH","XLV","FTXH","LU2468319806.SGD","IXJ","LU1629891620.HKD","IE00B4R5TH58.HKD","IE0001KFT4U8.USD","LU1732799900.SGD","LU0345770993.USD","LU1043141123.HKD","VHT","LU0203345920.USD","GDOC","SG9999001176.USD","IE000MB6IJN5.SGD","LU1267930813.SGD","LU2602419157.SGD","LU0545562505.USD","JNJ","BK4568","LU1221951129.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667296846","title":"Contineum 股價下跌 9.9%，原因是其與強生合作研發的抗抑鬱藥中期臨床試驗失敗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667296846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667296846?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 01:17","pubTimestamp":1789492646,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0124676726.USD","IXJ","JNJ","LU1244550577.SGD","LU0345769631.USD","LU1629891620.HKD","LU1162221912.USD","IHE","LU0792757196.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","FTXH","GDOC","VHT","IE00BFXG1179.USD","IBBQ","LU1032955483.USD","RXL","BK4568","IBBJ","FHLC","XLV","IE000SO60NU8.SGD","IE00BFTCPJ56.SGD","LU0545562505.USD","BMED","LU0203345920.USD","LU1430594728.SGD","LU1585245621.USD","MEDX","LU0432979614.USD","TRUH","IYH","LU2403377893.USD","LU0820561818.USD","LU1674673691.USD","LU2417539215.USD","LU0072461881.USD","LU0289739699.SGD","PJP","PSYK","LU0689626769.HKD","MDTX","IE00BJT1NW94.SGD","IE00B42XCP33.USD","LU0889566641.SGD","LU1989771016.USD","LU1929549753.HKD","LU1228905540.USD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU0114720955.EUR","IE00BSNM7G36.USD","BK4139","BK4583","LU1023059063.AUD","LU0289739699.SGD","LU0965509283.SGD","LU1066051498.USD","LU1778281490.HKD","LU0859254822.USD","LU1430594728.SGD","MEDI","LU0320765992.SGD","LU0965509101.SGD","LU2357627491.SGD","SG9999015986.USD","IE00B19Z3581.USD","IE00B3T34201.USD","LU2089984988.USD","BBH","LU2468319806.SGD","GILD","BK4568","LU0122379950.USD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU1057294990.SGD","BK4585","BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1674673428.USD","LU1934455277.USD","LU1585245621.USD","LU0109394709.USD","BK4550","LU0058720904.USD","LU0882574055.USD","LU1934455863.HKD","TMED","LU1061106388.HKD","LU1934455194.USD","LU0965508806.USD","TBXU","LU1674673691.USD","BK4566","LU1066053197.SGD","LU1037948897.HKD","LU0234570918.USD","LU0965509010.AUD","LU0823416689.USD","LU1037948541.HKD","IBBQ","BIB","LU0889565916.HKD","LU1839511570.USD","SG9999015952.SGD","BK4532","BMED","IE00B7SZLL34.SGD","LU0861579265.USD","SG9999015978.USD","LU2087621335.USD","BK4578","IE0002270589.USD","LU2112291526.USD","LU2324357040.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU0861579265.USD","LU1571399168.USD","LU1674673691.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","MEDI","IE00BSNM7G36.USD","LU1839511570.USD","IBBQ","TMED","LU1778281490.HKD","BK4583","IE00B19Z3B42.SGD","BBH","LU2468319806.SGD","TBXU","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1061106388.HKD","LU1066051498.USD","LU0320765992.SGD","IBB","LU1037948541.HKD","BK4578","LU2112291526.USD","LU0058720904.USD","SG9999015978.USD","IE00BKVL7J92.USD","BK4566","BMED","LU0965508806.USD","LU0965509283.SGD","LU1023059063.AUD","LU1585245621.USD","LU1934455194.USD","LU0114720955.EUR","BIB","LU0859254822.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","LU0965509010.AUD","BK4550","LU2089984988.USD","LU0122379950.USD","BK4139","BK4568","IE00B3T34201.USD","LU0109394709.USD","LU0234570918.USD","SG9999015986.USD","LU2357627491.SGD","LU1934455277.USD","LU1037948897.HKD","LU0289739699.SGD","LU2087621335.USD","LU1934455863.HKD","BK4532","LU2324357040.USD","LU0823416689.USD","IE0002270589.USD","GILD","SG9999015945.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623020","title":"吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623020","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:11","pubTimestamp":1789485099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0859254822.USD","IE0002270589.USD","TBXU","BK4550","LU1057294990.SGD","LU1066051498.USD","LU1839511570.USD","IBBQ","LU0234570918.USD","LU0965509283.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","LU2112291526.USD","SG9999015978.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU1934455277.USD","BK4532","LU2324357040.USD","LU0289739699.SGD","BMED","BK4566","IBB","BK4568","LU0965509101.SGD","BIB","LU1066053197.SGD","BK4139","GILD","LU1037948897.HKD","LU1585245621.USD","LU1674673691.USD","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LU1674673428.USD","TMED","LU0114720955.EUR","SG9999015952.SGD","LU1061106388.HKD","LU1037948541.HKD","SG9999015945.SGD","LU0965509010.AUD","BK4588","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","MEDI","BBH","LU1430594728.SGD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}